AACR 2023 | Assessing cabozantinib with PARP inhibitors in DDR mutant-tumors

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses strategies to enhance the efficacy of PARP inhibitors in patients who have progressed on PARP inhibitors. Addition of the ATR inhibitor cabozantinib with three PARP inhibitors was found to re-sensitize tumors to PARP inhibitors without added toxicity. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.